Differential Functional Activity of 5-hydroxytryptamine Receptor Ligands and Beta Adrenergic Receptor Antagonists at 5-hydroxytryptamine1B Receptor Sites in Chinese Hamster Lung Fibroblasts and Opossum Renal Epithelial Cells
Overview
Authors
Affiliations
Functional activity of 5-hydroxytryptamine (5-HT) receptor ligands and beta adrenergic receptor antagonists was studied at 5-HT1B receptor sites in Chinese hamster lung (CHL) fibroblasts by measuring two cellular responses: inhibition of forskolin-stimulated cyclic AMP formation and potentiation of basic fibroblast growth (BFGF) induced mitogenesis. A good correlation was found between the potency of agonists to inhibit forskolin-induced cyclic AMP formation and their potency to potentiate bFGF-induced thymidine incorporation in CHL fibroblasts. Potent agonist activity was measured with 5-methoxy-3,1,2,3,6-tetrahydro-4-pyidinyl- 1H-indole (RU 24,969), 5-carboxamidotryptamine (5-CT), 3-(1,2,5,6)-tetrahydro-4-pyridyl-5-pyrrolo(3,2-b)pyril-5-one (CP 93,129) and 5-HT, whereas sumatriptan displayed weak agonist activity at concentrations different from its binding affinity for 5-HT1B binding sites. In contrast to the observed 5-HT1B receptor-mediated agonist activity in opossum kidney cells for metergoline and the beta adrenergic receptor antagonists: cyanopindolol, 4-(3-tert-butyl-amino-2-hydroxypropoxy)-indole-2 carbonic acid isopropyl ester (SDZ 21,009), isamoltane, (-)-propranolol and (-)-pindolol, antagonist activity at 5-HT1B receptor sites was yielded in CHL fibroblasts in accordance with the reported observations at rat brain 5-HT1B receptors. Methiothepin was the only compound that antagonized both the opossum kidney cell and CHL fibroblast 5-HT1B receptor-mediated responses although the antagonist effect was more pronounced in CHL fibroblasts.(ABSTRACT TRUNCATED AT 250 WORDS)
Tomasini-Johansson B, Johnson I, Hoffmann F, Mosher D Matrix Biol. 2012; 31(6):360-7.
PMID: 22986508 PMC: 3508085. DOI: 10.1016/j.matbio.2012.07.003.
Odagaki Y, Toyoshima R Naunyn Schmiedebergs Arch Pharmacol. 2006; 372(5):335-45.
PMID: 16491386 DOI: 10.1007/s00210-006-0041-x.
Markou A, Harrison A, Chevrette J, Hoyer D Psychopharmacology (Berl). 2004; 178(2-3):133-42.
PMID: 15452682 DOI: 10.1007/s00213-004-2008-2.
Pauwels P, Wurch T, Palmier C, Colpaert F Naunyn Schmiedebergs Arch Pharmacol. 1996; 354(2):136-44.
PMID: 8857590 DOI: 10.1007/BF00178713.
Pauwels P, Palmier C, Wurch T, Colpaert F Naunyn Schmiedebergs Arch Pharmacol. 1996; 353(2):144-56.
PMID: 8717154 DOI: 10.1007/BF00168751.